Chau Khuong

Chau Q. Khuong joined OrbiMed Advisors in 2003 and is a Partner on the Private Equity team. Chau Khuong has experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer Associate in the New Ventures technology transfer group at Columbia University. At OrbiMed, Chau Khuong was actively involved investments in Arius Research, Inc. (acquired by Roche in 2008), Peninsula Pharmaceuticals, Inc. (acquired by Johnson & Johnson, Inc., in 2005), Cerexa, Inc. (acquired by Forest Laboratories, Inc., in 2007), Adiana, Inc. (acquired by Cytyc Corporation in 2007), Avanir (NASDAQ: AVNR), and Biodel, Inc. (NASDAQ: BIOD). He currently serves as Director or Observer on the Corporate Boards at Cerapedics, Glaukos Corporation, Intercept Pharma, Sonendo, and Pieris AG. Chau Khuong holds a BS in molecular biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.